Ambiq Micro heads into its third-quarter report with an unusual problem for a young, loss-making chip company. Customers want more of its ultra-low-power processors than it can build. Last quarter management described a step change in demand and raised both its revenue and margin outlook. It also said that second-half shipments would be capped by tight capacity in wafers, packaging, substrates and testing. The stock has since fallen about 34%, while the S&P 500 slipped roughly 3%. That gap frames the report. The business narrative improved, but the market has priced the shares as though something is going wrong.

The Street is looking for revenue of about $36.7 million, roughly double the $18.2 million of the year-ago quarter. That sits squarely inside management's guidance of $36 million to $37 million, which implied about 100% growth. The consensus calls for a non-GAAP loss of 16 cents a share. The whisper number is a loss of 10 cents, a meaningfully better result than consensus. The more demanding expectation, then, is on profitability rather than on sales. Because management said revenue is limited by supply rather than demand, a large top-line beat looks less likely this quarter. A capacity-constrained company can only ship what it can build, so a modest beat near the top of the range would be a reasonable outcome. A blowout would actually raise questions about how binding the constraints really were.

That shifts attention to margins and spending. Non-GAAP gross margin has climbed for four straight quarters to 47.2%, beating the prior guide, and management upgraded its full-year view from flat to modest improvement. Holding margins near that level would show that rising component and substrate costs are being absorbed, possibly through pricing power that tight supply should provide. Erosion would challenge one of the cleaner pieces of the story. Operating expenses are guided up to $24 million to $25 million from the $21 million to $22 million range guided for the second quarter. Much of that reflects recurring intellectual property purchases tied to the next-generation Atomic 110 and Apollo 340 platforms. Spending at or below guidance, alongside steady margins, is the path to beating the whisper.

The operational questions go beyond the quarter's numbers. Management framed full-year revenue at about $135 million and said unmet demand would slide into 2027. Investors should listen for signs that capacity is loosening or that the company has secured more of it, since that determines whether the deferred revenue actually materializes. The new Apollo 330 Plus and Apollo 510 Lite chips launched with backlog and were slated to begin contributing this quarter. Early commentary on their ramp would help show that the product cycle is broadening. So would continued strength outside the top three customers, where sales grew 143% last quarter, along with progress toward more than doubling non-wearable revenue this year. China exposure, which rose to about 14% of sales, is another detail worth tracking. The finance chief also declined to reaffirm an earlier hope of reaching profitability in late 2027 or early 2028, so any clarity there would matter.

Sentiment has cooled noticeably, moving from mildly bullish before the last report to slightly bearish now. The shares trade at $43.31, below their 200-day moving average of $53.63 and under the $46.25 low set since the last report. That is a stock trading below its post-earnings range, not one testing a breakout, and the lower bar could work in Ambiq's favor if the report is clean.

Ultimately, the report needs to show that supply limits are delaying growth rather than eroding it. A quarter that lands within guidance with intact margins, disciplined spending and a credible path to more capacity in 2027 would keep the story whole. Signs that constraints are tightening further or that costs are eating into gross margin would give the market's skepticism more grounding.